ReviewNeurogenetics2026
Clinical and neuroimaging features in a case of cerebrotendinous xanthomatosis with a CYP27A1 genotype newly identified in morocco: a literature review of African cases.
Review in Neurogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebrotendinous xanthomatosis (CTX; OMIM 213700) is a rare autosomal recessive neurometabolic disorder caused by pathogenic variants in CYP27A1 (OMIM 606530), encoding sterol 27-hydroxylase. Enzymatic deficiency impairs bile acid synthesis and leads to systemic accumulation of cholestanol and cholesterol, resulting in progressive multisystem involvement. Neurological manifestations often coexist with tendon xanthomas, cataracts, and normocholesterolemia, forming a characteristic clinical triad. Early treatment with chenodeoxycholic acid can prevent or reverse neurological decline, emphasizing the need for timely recognition and genetic confirmation. We report a 25-year-old Moroccan woman presenting with bilateral cataracts and progressive neurological deterioration from age 23, characterized by ataxia, intention tremor, and spasticity. Examination revealed Achilles tendon xanthomas, xanthelasma, and increased muscle tone. Biochemical analysis demonstrated elevated cholestanol levels, and brain MRI showed diffuse white matter hyperintensities. Genetic testing identified a homozygous splice donor site variant in CYP27A1 (NC_000002.11(NM_000784.4):c.446 + 1G > A), confirmed by parental segregation analysis. Comparison with three previously described patients carrying the same variant revealed consistent ocular and cerebellar involvement but notable variability in age at onset, neurological severity, and systemic features. Review of African CTX cases demonstrated presentations ranging from the typical triad (cataracts, tendon xanthomas, neurological decline) to milder or neuropsychiatric forms without xanthomas. North African cases often share founder genotypes and show severe neurological impairment, whereas sub-Saharan cases exhibit broader expressivity. These patterns suggest regional genetic influences and highlight ongoing diagnostic delays across Africa.
Indexed as
Identifiers
41582284What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.